TSX: HAE
MONTREAL, Sept. 18 /CNW Telbec/ - Haemacure Corporation (TSX: HAE)
announced today that Joseph Galli, Chairman and Chief Executive Officer of
Haemacure, will present at the Sachs 8th Annual Biotech in Europe Investor
Forum, being held September 23-24 in Zurich, Switzerland. Mr. Galli will
present a corporate progress report, including an update on the Company's lead
product candidate, Hemaseel(R)HMN (fibrin sealant). The Haemacure presentation
is scheduled to begin at 12:10 p.m. local time on Tuesday, September 23rd.
Information on the Forum is available at
http://www.sachsforum.com/zurich08/index.html.
About Haemacure
Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical hemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase
III clinical trials during the first half of 2009. Haemacure's second product
candidate is thrombin, a component of its fibrin sealant, now in preclinical
stage. Follow-on development will focus on the use of its fibrin sealant in
adhesion prevention, aesthetics, combination with biomaterials, drug delivery,
regenerative medicine, skin graft fixation for burn injuries and wound
management. Haemacure has discovered eleven additional specialty proteins and
enzymes in one if its two plasma fractions and seeks to advance these proteins
and enzymes through partnerships with pharmaceutical and biotechnology
companies. Haemacure is headquartered in Montreal, Quebec and operates offices
in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is
traded under stock symbol HAE on the TSX.
Forward-looking Statements
Certain of the statements contained in this news release are
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation or otherwise. Consequently,
actual future results may differ materially from the anticipated results
expressed in the forward-looking statements. Haemacure disclaims any intention
or obligation to update these statements.
